"We are confident that this addition of resources will set the foundation for expanding the breadth of services ERT provides for global clinical trials.” said Robert Brown, Vice President, Business Development Asia-Pacific at ERT.
Philadelphia, PA (PRWEB) May 14, 2013
ERT, a leading global provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development, today announced the addition of local resources to its fully-owned subsidiary, ERT Asia Group, Ltd. The Japan-based project management and business development team will further enhance the quality of centralized services ERT is known for providing throughout Asia. The team will work out of ERT’s new office in Ginza, Chuo-ku, Tokyo.
The Japan-based operations staff comes primarily from ERT’s 7-year partnership with Site Support Institute (SSI), a Japanese Site Management Organization and subsidiary of CMIC Holdings Co., Ltd. Employees transitioning from SSI have significant experience delivering ERT's project management, business development, and customer care services. This staff has several years of experience working with ERT’s customers in Japan, which includes 36 biopharmaceutical companies and over 3,250 Japan-based investigators in 250 clinical trials conducted to date. Therefore, there will be no disruption to the services ERT is currently delivering as it expands direct support.
“The relationship we have formed with SSI and the experience these employees bring to ERT will enable us to seamlessly deliver personalized support to clinical trial sponsors and investigative sites and improve on our responsiveness in support of Japan-based trials,” said Robert Brown, Vice President, Business Development Asia-Pacific at ERT. “We are very excited to welcome these associates to the ERT team and are confident that this addition of resources will set the foundation for expanding the breadth of services ERT provides for global clinical trials.”
The Tokyo office will support the growing number of biopharmaceutical companies who are utilizing ERT’s clinical endpoint solutions in Japan-based trials. ERT’s suite of centralized services are each experiencing greater demand in the region, including cardiac safety, respiratory services, Clinical Outcome Assessments (COAs), suicide risk assessment, and scientific consulting in support of these services.
To support biopharmaceutical researchers’ ongoing educational needs, ERT has expanded the Japanese version of its corporate website with recordings of two recently conducted webinars which have been translated into Japanese:
- “Use of Cardiac Safety Data in Early Phase Trials to Supplement or Replace a Thorough QT Trial”
- “Are eDiaries Really Better than Paper-based Patient Reported Outcomes?”
To access these complimentary webinars, and to learn more about ERT’s clinical endpoint solutions and Asian experience visit http://www.ertjapan.jp.
ERT (http://www.ert.com) is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services, and consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process throughout the product lifecycle. ERT delivers the most widely deployed solutions in centralized cardiac safety, respiratory services, suicide risk assessment and Clinical Outcome Assessments (COA) – which includes patient, clinician, and observer reported outcomes. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes, and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products. ERT is a global organization with headquarters in Philadelphia, PA and offices throughout the U.S., U.K., Japan, and Germany.